Immunicon Corp

Immunicon — Investor Presentation (September 2006)

26 slides from Immunicon's investor presentation, Sep 26, 2006

  1. Slide 1: Management Presentation September 2006

    Slide 1: Management Presentation September 2006

    Management Presentation September 2006 Cellular Information for Better Healthcare Circulating Tumor Cells Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain forward-looking statements that reflect management ’ s current views and opinions as to the status of the Company ’ s products, clinical trials, regulatory approval process, product development, research programs and other future events and op

  3. Slide 3: Immunicon Value Proposition

    Slide 3: Immunicon Value Proposition

    Immunicon Value Proposition Immunicon develops and commercializes proprietary cell- and molecular- based human diagnostic and life science research products Cancer products sold through Veridex, a Johnson & Johnson company – Received FDA clearances for our instruments and CellSearch™ Circulating Tum

  4. Slide 4: CellTracks Products for Cellular Analysis

    Slide 4: CellTracks Products for Cellular Analysis

    CellTracks ® Products for Cellular Analysis Circulating Tumor Cell Kit Sample Collection and Preservation Standardized Rare Cell Capture Endothelial Cell Kit Sample Analysis Kits for Cell Counting

  5. Slide 5: CellTracks Products: CEC Kit, Profile Kit

    Slide 5: CellTracks Products: CEC Kit, Profile Kit

    CEC Kit Profile Kit CellTracks ® Products Marker Reagents for Characterization for Targeted Therapy * HER-2/neu * EGFr * IGF-1R * bcl-2 * M30 * other candidates with Pharma Enrichment Kits for Downstream Molecular Analysis FISH in cartridge (in development) Cancer Confirmation Gene Amplification Hea

  6. Slide 6: CTCs as a "Real-Time Biopsy"

    Slide 6: CTCs as a "Real-Time Biopsy"

    CTCs as a “ Real-Time Biopsy ” Blood Test Most tumors are of epithelial cell origin: Isolation of epithelial cells may mean pan - carcinoma capability Count Phenotype & Genotype Assess Prognosis Direct Therapy Monitor Disease Diagnose Specify Therapy Circulating Tumor Cells (CTCs) and Associated Mar

  7. Slide 7: Circulating Tumor Cells Predict Survival

    Slide 7: Circulating Tumor Cells Predict Survival

    Circulating Tumor Cells Predict Survival Time from Baseline (Months) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Logrank p < 0.0001 21.9 Months 10.9 Months > 5 CTCs n=87 (49%) <5 CTCs n=90 (51%) NEJM 2004, ASCO 2004 / 2005 Before initiation of therapy

  8. Slide 8: Change in CTCs Predict Survival

    Slide 8: Change in CTCs Predict Survival

    Change in CTCs Predict Survival Package Insert, October 2005 Clinical Cancer Research, July 2006 green vs. red p=0.0001 green vs. blue p=0.3188 green vs. orange p=0.0014 blue vs. red p=0.0002 22.6 mo. 19.8 mo. 10.6 mo. 4.1 mo. Time from Baseline (months) < 5 CTCs at First and Last Draw 83 (47%) >5 C

  9. Slide 9: Any CTCs Impact Survival: Treat to Zero!

    Slide 9: Any CTCs Impact Survival: Treat to Zero!

    Any CTCs Impact Survival: Treat to Zero! CTC / 7.5 ml blood Median 95% Low limit 95% Upper limit 29% 71% 61% 56% 51% 48% 45% 43% 43% 40% 36% =0 >1 >2 >3 >5 >7 >8 >9 >6 >4 >10 Median 95% Low limit 95% Upper limit =0 >1 >2 >3 >5 >7 >8 >9 >6 >4 >10 223 patients San Antonio Breast Cancer Symposium 2005

  10. Slide 10: A New Standard for Cancer Disease Management

    Slide 10: A New Standard for Cancer Disease Management

    A New Standard for Cancer Disease Management Future standard: Number, protein expression, and/or gene expression of CTCs better reflects efficacy of treatment Current standard: Radiologist measures changes in lesions on a CT scan to assess tumor burden increase/decrease Objective, quantitative 3-4 w

  11. Slide 11: CTC versus CT Scans to Predict Survival

    Slide 11: CTC versus CT Scans to Predict Survival

    CT Scans 11.9 +5.7 weeks *Centralized Review by Two Independent Radiologist. Third Radiologist was used in cases of disagreement (11%) CTC versus CT Scans to Predict Survival CCR in press / ASCO 2005 23.8 Months 6.4 Months S/PR & <5CTCs n=84 (61%) PD & <5CTCs n=20 (14%) S/PR & >5CTCs n=12 (9%) PD &

  12. Slide 12: Personalized Medicine: Her2 and targeted therapy selection

    Slide 12: Personalized Medicine: Her2 and targeted therapy selection

    Her2 - Her2 + Her2 ++ Her2 +++ Time (weeks) Taxol Herceptin Int J Oncol 21: 1111-1118, 2002 “Personalized Medicine” Enables selection of targeted therapies

  13. Slide 13: Cancer Confirmatory Test

    Slide 13: Cancer Confirmatory Test

    Leukocyte Tumor Cell Cancer Confirmatory Test Chromosome 1 Chromosome 7 Chromosome 8 2 x1, 2 x 7, 2 x 8 3 x1, 5 x 7, 4 x 8

  14. Slide 14: Assessment of Treatment Targets on CTCs

    Slide 14: Assessment of Treatment Targets on CTCs

    PNAS , Cytokeratin Her-2 Her-2 protein CEP 17 Her-2 gene CEP 17 / Her-2 gene 1+: 1.0 3+: 3.5 2+: 1.7 Assessment of Treatment Targets on CTCs 101: 9393-9398, 2004

  15. Slide 15: Significant Clinical Utility of Circulating Tumor Cells

    Slide 15: Significant Clinical Utility of Circulating Tumor Cells

    Significant Clinical Utility of Circulating Tumor Cells Patient Management Early evidence of treatment failure: gives the oncologist information to change therapy within weeks Predictive at any time point during treatment CTCs predict survival time in patients undergoing chemo & hormonal therapy CTC

  16. Slide 16: Advanced Technology for Simple Cell Counting

    Slide 16: Advanced Technology for Simple Cell Counting

    Instrument Rapid, accurate automated counts Simple to use 2-color analysis Uses proven technology Kits Simple cell counting (ViaSure) Immunomagnetic Selection (IMS) Isolate and count specific cells Advanced Technology for Simple Cell Counting

  17. Slide 17: Research and Clinical Development Programs

    Slide 17: Research and Clinical Development Programs

    Research and Clinical Development Programs Colorectal cancer – endpoints achieved! Prostate cancer: 2Q07 FDA submission on 200 patient study Research studies – CTCs in early stage breast cancer and colorectal cancer – Impact on survival of changing therapy based on CTCs (SWOG) Develop FISH technolog

  18. Slide 18: Success in Pivotal Clinical Trial in Metastatic Colorectal Cancer

    Slide 18: Success in Pivotal Clinical Trial in Metastatic Colorectal Cancer

    Success in Pivotal ClinicalTrial in Metastatic Colorectal Cancer Primary and secondary endpoints were achieved – Primary – agreement with imaging – Secondary - predict progression-free survival and overall survival. Large, multi-center trial – 481 patients; 55 sites in US and Europe Anticipate late

  19. Slide 19: Product Commercialization

    Slide 19: Product Commercialization

    Product Commercialization Oncologists Pathologists/laboratories Pharma Services Molecular Diagnostics Products and Services Life Science Research Instruments and Kits Infectious Disease Diagnostics

  20. Slide 20: Summary of instrument shipments and sales

    Slide 20: Summary of instrument shipments and sales

    Summary of instrument shipments and sales Year ended Six months ended Cumulative from launch June 30, 2006 to June 30, 2006 Instrument shipments CellTracks Analyzer II CellSpotter (6) Total Analyzers CellTracks AutoPreps Instruments sold (1) Total CellTracks Analyzer II Total CellSpotter Total Analy

  21. Slide 21: System Placements, by Customer/Geography

    Slide 21: System Placements, by Customer/Geography

    System Placements, by Customer/Geography 8.5 6.5 Veridex internal use Pharma/CRO Reference Lab Hospital/Institute Total Shipments Total Japan/ Asia EU USA As of 6/30/06 Third party: 47 Total Placements: 55.5

  22. Slide 22: Financial Status

    Slide 22: Financial Status

    Financial Status Cash burn guidance for 2006 - $20 to $22 million Headcount at June 30, 2006 = 104 Borrowing capacity of $12.0 million @ 6/30/06 June 30, 2006 December 31, 2005 Cash and cash equivalents 33,931 $ 44,098 $ 6 months June 2006 6 months June 2005 Product & service revenue 3,379 $ 1,232 $

  23. Slide 23: Milestones Achieved

    Slide 23: Milestones Achieved

    Milestones Achieved Publications in major peer reviewed journals Q3/04 – NEJM, CCR, JCO U.S. in vitro diagnostic (IVD) launch Q3/04 510(k) clearance of expanded data Oct. 2005 Trial in colorectal cancer – endpoints met Sept 2006 Trial in prostate cancer enrollment complete Jan. 2006 Kreatech license

  24. Slide 24: Upcoming Milestones/Presentations

    Slide 24: Upcoming Milestones/Presentations

    Upcoming Milestones/Presentations Colorectal cancer 510(k) Q4 ’ 06; Q1 ’ 07 Prostate cancer data/510(k) H1/2007 Upcoming Scientific meetings – San Antonio Breast Cancer Symposium Dec. 2006 UBS Life Sciences Conference Presentation Sep. 2006 EasyCount ™ System launch H1/2007 Launch first CTC FISH ass

  25. Slide 25: Immunicon Value Proposition

    Slide 25: Immunicon Value Proposition

    Immunicon Value Proposition Immunicon develops and commercializes proprietary cell- and molecular- based human diagnostic and life science research products Cancer products sold through Veridex, a Johnson & Johnson company – Received FDA clearances for our instruments and CellSearch™ Circulating Tum

  26. Slide 26: Contact Information

    Slide 26: Contact Information

    Contact Information 3401 Masons Mill Road, Suite 100 Huntingdon Valley, Pennsylvania 19006 phone 215.830.0777 fax 215.830.0751 web www.immunicon.com

Source: SEC EDGAR · 8-K filed Sep 26, 2006

More decks from Immunicon Corp